Orthocell (ASX:OCC) has reached a pivotal milestone in its international expansion, completing the first surgical case using its Remplir nerve repair device within the United States Department of Defence and Veterans Affairs hospital network.
The procedure, conducted at a military base hospital in Ohio, marks the rapid clinical adoption of the technology following the company’s recent procurement approval announced just two days prior.
By transitioning from regulatory approval to real-world clinical use in under 48 hours, the company has demonstrated high levels of surgeon engagement and a robust logistics framework.
The DoD and VA network provides a massive scale for adoption, encompassing 51 military hospitals and 170 VA medical centres nationwide.
The integrated system offers Orthocell a streamlined pathway to reach thousands of veterans and active-duty service members requiring advanced regenerative nerve treatments.
The swift implementation is supported by Orthocell’s extensive US distributor footprint, which currently spans 17 states.
The partners are providing essential in-theatre case support and efficient onboarding to ensure seamless integration into American surgical suites.
At the time of reporting, Orthocell's share price was $1.04.